Effect of Anti-epileptic Drugs on Etonogestrel-releasing Implant Pharmacokinetics in Women With Epilepsy

University of Sao Paulo

Status and phase: Unknown; Phase 4

Conditions: Contraception; Drug Interactions

Treatments: Drug: Carbamazepine-Implant; Drug: Implant; Drug: Topiramate-Implant

Study type: Interventional

Funder types: Other

Identifiers

NCT03307863

2.140.103

Details and patient eligibility

About

Data on the interaction between the etonogestrel (ENG) implant and antiepileptic drug (AED) regimen are scarce. We will evaluated the effect of 2 AED regimens (1 including carbamazepine and the other topiramate) on the pharmacokinetic (PK) parameters of an ENG-releasing implant in women with epilepsy.

Enrollment: 69 estimated patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• women 18- 45 years old;
• with regular menstrual cycles;
• with BMI between 18 and 29.9 (kg/m2);
• who has selected the ENG implant as a contraceptive method;
• Using a stable antiepileptic drug regimen including carbamazepine or topiramate for ate least 3 months (only for women with epilepsy).

Exclusion criteria

• use of short-acting hormonal contraceptives in the month prior to enrollment;
• use of depomedroxyprogesterone acetate in the 6 months prior to enrollment;
• women with conditions classified as category 3 and/or 4 for etonogestrel implant use according to the World Health Organization Medical Eligibility Criteria for contraceptive use;
• drug or alcohol addiction;
• use of other drugs metabolized by CYP3A4 30 days prior to enrollment;
• non adherence to antiepileptic drug regimen (only for women with epilepsy);
• illiteracy

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

69 participants in 3 patient groups

Carbamazepine-Implant

Experimental group

Description:

Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted

Treatment:

Drug: Carbamazepine-Implant

Topiramate-Implant

Experimental group

Description:

Women with epilepsy using topiramate for at least 3 months will have an etonogestrel-releasing implant inserted

Treatment:

Drug: Topiramate-Implant

Implant

Active Comparator group

Description:

Women without epilepsy and not using an anti-epileptic drug will have an etonogestrel-releasing implant inserted

Treatment:

Drug: Implant